Form D · Biotechnology
Converge Biotech, Inc.
Miami, FL · CIK 0001579833
Offering snapshot reported Jul 12, 2013 · SEC filing
- Reported sold
- Yet to sell Offering amount: $1M
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 12, 2013 | Amendment | Yet to sell | No comparison | 0 | SEC filing |
| Jul 10, 2013 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Equity, Debt, Other
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0 (estimated)
- Finders' fees
- $0 (estimated)
- Form D file number
- 021-199358
Preferred Shares
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| None | None |
Source: Form D, filed Jul 12, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Paul Latta | Director, Executive, Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1450 Nw 10 Th Ave.
Miami, FL, 33136
Miami, FL, 33136